Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once-daily, single-tablet regimen for treatment of HIV-1 infection. The efficacy/safety of switching to D/C/F/TAF ver...

Source: AIDS Research and Therapy - August 29, 2019 Category: Infectious Diseases Authors: Gregory D. Huhn, Joseph J. Eron, Pierre-Marie Girard, Chloe Orkin, Jean-Michel Molina, Edwin DeJesus, Romana Petrovic, Donghan Luo, Erika Van Landuyt, Erkki Lathouwers, Richard E. Nettles, Kimberley Brown and Eric Y. Wong Tags: Research Source Type: research